FDA’s Advisory Committees Just Can’t Say “No”
Who says an advisory committee stop is a risky proposition? FDA’s advisors have voted in favor of approval on each of the last 12 products they’ve reviewed.
You may also be interested in...
After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.
FDA advisory committee narrowly endorses CV mortality benefit claim for Boehringer/Lilly's diabetes drug Jardiance, but some panelists question wisdom of relying on study originally designed for cardiovascular safety to support a post-marketing superiority claim.
Clovis Oncology Inc. on May 5 disclosed the FDA notified the company to expect its application for its experimental lung cancer drug rociletinib to be rejected – something that was widely expected on Wall Street after the firm failed in April to convince a federal panel of experts to back the medicine. Clovis, which is cutting its staff by 35% in the wake of the FDA's snub, now turns its attention to its investigational ovarian cancer drug rucaparib.